ACC 2023 | Subanalysis of the REVIVED-BICS Study2

This study demonstrated that coronary angioplasty does not entail any benefit in chronic stable angina over optimal medical therapy in those with impaired ventricular function (EF >35%) with extensive coronary artery disease and viable myocardium.

ACC 2023 | Subanálisis del Estudio REVIVED-BICS2

Dr. Divaka Perera performed a subanalysis of said study.

At the time of the study, the amount of viability and whether it could impact follow-up was unknown. For that reason, MRI and viability on stress-echo were analyzed.

While they found that viability did not predict mortality or hospitalization for heart failure, they observed that every 10% increase in scar volume increased the risk of events that comprised the primary endpoint by 18% (hazard ratio [HR]: 1.18, 95% confidence interval [CI]: 1.04-1.33, p = 0.009), and that evolution was better in the group where EF improved (HR 0.63, 95% CI: 0.41-0.95; p = 0,029).

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of

Original Title: Effect Of Myocardial Viability, Percutaneous Coronary Intervention And Functional Recovery On Clinical Outcomes In The REVIVED-BCIS2 Randomized Trial.

Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology